Across TCGA pan-cancer cohorts, KCNJ8 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KCNJ8 data layer compared with 24 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KCNJ8 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated KCNJ8 expression acts as an unfavorable survival marker.
PDAC and LSCC are the cancer types where KCNJ8 mass-spec protein most reproducibly stratifies survival.